Literature DB >> 11286835

Radioimmunoguided imaging of prostate cancer foci with histopathological correlation.

R J Ellis1, E Y Kim, R Conant, D B Sodee, J P Spirnak, K H Dinchman, S Beddar, B Wessels, M I Resnick, T J Kinsella.   

Abstract

PURPOSE: We have previously presented a technique that fuses ProstaScint and pelvic CT images for the purpose of designing brachytherapy that targets areas at high risk for treatment failure. We now correlate areas of increased intensity seen on ProstaScint-CT fusion images to biopsy results in a series of 7 patients to evaluate the accuracy of this technique in localizing intraprostatic disease. METHODS AND MATERIALS: The 7 patients included in this study were evaluated between June 1998 and March 29, 1999 at Metrohealth Medical Center and University Hospitals of Cleveland in Cleveland, Ohio. ProstaScint and CT scans of each patient were obtained before transperineal biopsy and seed implantation. Each patient's prostate gland was biopsied at 12 separate sites determined independently of Prostascint-CT scan results.
RESULTS: When correlated with biopsy results, our method yielded an overall accuracy of 80%: with a sensitivity of 79%, a specificity of 80%, a positive predictive value of 68%, and a negative predictive value of 88%.
CONCLUSION: The image fusion of the pelvic CT scan and ProstaScint scan helped identify foci of adenocarcinoma within the prostate that correlated well with biopsy results. These data may be useful to escalate doses in regions containing tumor by either high-dose rate or low-dose rate brachytherapy, as well as by external beam techniques such as intensity modulated radiotherapy (IMRT).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286835     DOI: 10.1016/s0360-3016(00)01582-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Fused radioimmunoscintigraphy for treatment planning.

Authors:  Rodney J Ellis; Deborah A Kaminsky
Journal:  Rev Urol       Date:  2006

2.  The emergence of radioimmunoscintigraphy for prostate cancer.

Authors:  Thomas E Keane; Inger L Rosner; M Scott Wingo; David G McLeod
Journal:  Rev Urol       Date:  2006

3.  Complementary medicine, chemoprevention, and staging of prostate cancer.

Authors:  E David Crawford
Journal:  Rev Urol       Date:  2003

4.  Enhancing the utility of prostascint SPECT scans for patient management.

Authors:  Marilyn E Noz; Grace Chung; Benjamin Y Lee; Gerald Q Maguire; J Keith DeWyngaert; Jay V Doshi; Elissa L Kramer; Antoinette D Murphy-Walcott; Michael P Zeleznik; Noeun G Kwak
Journal:  J Med Syst       Date:  2006-04       Impact factor: 4.460

Review 5.  Prostate-specific membrane antigen-based imaging.

Authors:  Joseph R Osborne; Naveed H Akhtar; Shankar Vallabhajosula; Alok Anand; Kofi Deh; Scott T Tagawa
Journal:  Urol Oncol       Date:  2012-05-31       Impact factor: 3.498

Review 6.  The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients.

Authors:  Ashesh B Jani; Stanley L Liauw; Michael J Blend
Journal:  Clin Med Res       Date:  2007-06

7.  Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.

Authors:  Satyajit Kosuri; Naveed H Akhtar; Michael Smith; Joseph R Osborne; Scott T Tagawa
Journal:  Adv Urol       Date:  2012-05-28

8.  Focal Prostate Stereotactic Body Radiation Therapy With Correlative Pathological and Radiographic-Based Treatment Planning.

Authors:  Elisha Fredman; Bryan Traughber; Michael Kharouta; Tarun Podder; Simon Lo; Lee Ponsky; Gregory MacLennan; Raj Paspulati; Bradley Ellis; Mitchell Machtay; Rodney Ellis
Journal:  Front Oncol       Date:  2021-09-15       Impact factor: 6.244

Review 9.  Brachytherapy: update and results.

Authors:  Rodney J Ellis; Edward Kim
Journal:  Curr Urol Rep       Date:  2003-06       Impact factor: 2.862

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.